OTCMKTS:VVUSQ VIVUS (VVUSQ) Stock Price, News & Analysis $0.12 0.00 (0.00%) As of 12/17/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About VIVUS Stock (OTCMKTS:VVUSQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VIVUS alerts:Sign Up Key Stats Today's Range$0.12▼$0.1250-Day Range$0.12▼$0.1252-Week Range$0.07▼$4.55VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview VIVUS, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for metabolic health, sleep-disordered breathing and sexual health. Headquartered in Redwood City, California, the company’s mission centers on addressing conditions with significant unmet medical needs by advancing novel treatment options. VIVUS is publicly traded on the OTC Markets under the ticker VVUSQ. The company’s flagship product, Qsymia, combines phentermine and topiramate extended-release for chronic weight management in adults with obesity or overweight patients with weight-related comorbidities. Approved by the U.S. Food and Drug Administration in 2012, Qsymia marked VIVUS’s entry into the commercial marketplace and has since been licensed to partners for broader distribution. In the realm of sexual health, VIVUS in-licensed avanafil, marketed as Stendra, an FDA-approved therapy for erectile dysfunction, further diversifying its product portfolio and geographic footprint through strategic alliances. In addition to its marketed products, VIVUS maintains a clinical pipeline aimed at addressing sleep apnea and other cardiometabolic disorders. The company collaborates with academic institutions and industry partners to explore novel mechanisms of action and delivery formats. Leveraging licensing agreements, VIVUS extends its reach across North America, Europe and key Asian markets while maintaining a lean corporate structure. Its leadership team comprises professionals with extensive experience in drug development, regulatory affairs and commercial strategy.AI Generated. May Contain Errors. Read More Receive VVUSQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address VVUSQ Stock News HeadlinesVIVUS Announces QSYMIA® Now Available at Costco Pharmacies NationwideMay 27, 2025 | tmcnet.comVIVUS’ QSYMIA® to be Featured on Health Uncensored with Dr. DrewMarch 19, 2025 | markets.businessinsider.comMiss This Window And You Miss EverythingThere’s a moment in every crypto cycle when everything just clicks — and that moment is now. This is the phase when momentum builds, news turns bullish, and markets ignite. Inside The Crypto Code Workshop, you’ll get the roadmap to ride this wave — and $10 in free Bitcoin just for showing up.July 18 at 2:00 AM | Crypto Swap Profits (Ad)VIVUS and UpScriptHealth Announce Launch of ChooseQ.online for Access to Advanced Weight Management SolutionsOctober 30, 2024 | markets.businessinsider.comVIVUS Announces Commercialization of QSIVA® in Sweden, Denmark, Finland, Iceland, Norway, and PolandOctober 7, 2024 | markets.businessinsider.comTimber Rattlesnake vs. Eastern Diamondback: What Sets These Fanged Serpents Apart?August 19, 2024 | msn.comIcahn Enterprises L.P. (NASDAQ:IEP) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | msn.comWeight Loss Drugs Market Size to Hit US$ 45.35 Billion By 2032, With a Growing CAGR of 43.73% | Research by SNS InsiderJuly 23, 2024 | finance.yahoo.comSee More Headlines VVUSQ Stock Analysis - Frequently Asked Questions How have VVUSQ shares performed this year? VIVUS's stock was trading at $0.1174 at the beginning of 2025. Since then, VVUSQ shares have increased by 0.0% and is now trading at $0.1174. How do I buy shares of VIVUS? Shares of VVUSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:VVUSQ CIKN/A Webwww.vivus.com Phone650-934-5200Fax650-934-5389Employees57Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:VVUSQ) was last updated on 7/18/2025 by MarketBeat.com Staff From Our Partners[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredWhen your faith is put to the test, what will you do?Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VIVUS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.